last
centuri
wit
emerg
sever
previous
unknown
virus
lifethreaten
human
pathogen
sever
exampl
includ
hiv
ebola
lujo
recent
middl
east
respiratori
syndrom
mer
ebola
studi
describ
method
swift
gener
humanderiv
monoclon
antibodi
known
treatment
mer
infect
antibodi
gener
use
cellclon
technolog
immort
b
cell
human
donor
recov
mer
four
month
requir
initi
screen
b
cell
develop
stabl
cho
cell
line
suitabl
product
clinic
grade
antibodi
therebi
delin
rapid
pathway
develop
antivir
therapi
emerg
virus
current
antibodi
consid
clinic
develop
includ
prophylaxi
individu
risk
treatment
sever
merscov
infect
mer
highli
lethal
pulmonari
infect
caus
previous
unidentifi
coronaviru
cov
thought
infect
dromedari
camel
mer
first
surfac
april
viru
rapidli
identifi
two
independ
group
mer
also
belong
novel
subgroup
c
betacoronaviru
fig
merscov
spread
countri
caus
episod
infect
last
three
year
april
total
case
death
report
mostli
saudi
arabia
case
human
infect
transmit
direct
contact
camel
occur
direct
contact
mer
patient
hospit
inde
healthcar
exposur
seem
play
key
role
spread
merscov
outbreak
treat
virus
still
challeng
modern
medicin
effect
measur
combat
viral
diseas
prevent
vaccin
howev
observ
latest
ebola
outbreak
vaccin
develop
appli
suffici
rapidli
contain
acut
outbreak
given
danger
newli
emerg
virus
novel
strategi
need
develop
gener
rapidli
effect
treatment
interestingli
antibodybas
treatment
one
promis
approach
treatment
prevent
viral
diseas
emil
v
behr
kitasato
pioneer
use
passiv
antibodi
therapi
earli
show
hyperimmun
sera
anim
origin
could
protect
diphtheria
tetanu
serum
therapi
infect
follow
substitut
antibiot
discov
unfortun
use
polyclon
anim
sera
associ
sever
side
effect
includ
hypersensit
reaction
serum
sick
result
administr
larg
amount
anim
protein
problem
led
replac
anim
sera
human
hyperimmun
immunoglobulin
prepar
use
prevent
treat
prevent
cytomegaloviru
varicella
zoster
viru
hepat
b
viru
respiratori
syncyti
viru
rsv
infect
high
risk
popul
importantli
respigam
hyperimmun
immunoglobulin
product
rsv
replac
synagi
first
monoclon
antivir
antibodi
market
clinic
studi
show
patient
sever
pneumonia
caus
viral
infect
convalesc
sera
confer
therapeut
benefit
administ
patient
sever
infect
spanish
influenza
pneumonia
sarscov
influenza
influenza
viru
recent
ebola
outbreak
attempt
collect
therapeut
antibodi
serum
recov
mer
patient
well
peopl
live
patient
health
worker
contact
howev
recent
discov
antibodi
titer
convalesc
plasma
low
produc
therapeut
effect
commun
dr
yaseen
arabi
merscov
research
initi
workshop
held
septemb
riyadh
thu
monoclon
antibodi
ideal
altern
hyperimmun
sera
hyperimmun
immunoglobulin
prepar
produc
immort
memori
b
cell
epsteinbarr
viru
ebv
fuse
b
cell
appropri
partner
cell
produc
hybridoma
method
low
effici
altern
strategi
develop
altern
includ
human
murin
monoclon
antibodi
protein
engin
select
human
antibodi
phage
display
librari
well
immun
transgen
mice
carri
human
immunoglobulin
loci
combin
product
monoclon
antibodi
use
hybridoma
technolog
although
method
led
develop
sever
therapeut
monoclon
antibodi
cytokin
surfac
antigen
impact
infecti
diseas
therapi
less
success
sever
advantag
use
human
memori
b
cell
product
monoclon
antibodi
antibodi
fulli
human
ii
memori
b
cell
readili
access
blood
persist
lifetim
iii
low
risk
crossreact
selfantigen
iv
human
immun
respons
direct
virul
pathogen
v
function
assay
use
isol
antibodi
base
function
agnost
approach
need
use
molecular
target
bait
antibodi
isol
vi
process
fast
lanzavecchia
group
institut
research
biomedicin
irb
bellinzona
describ
improv
method
ebv
transform
human
b
cell
method
call
cellclon
technolog
wwwhumabscom
optim
use
isol
antibodi
larg
set
viral
bacteri
pathogen
tabl
importantli
antibodi
isol
approach
test
clinic
trial
partnership
pharmaceut
industri
cellclon
technolog
also
use
isol
potent
monoclon
antibodi
abl
neutral
merscov
infect
second
patient
ever
report
mer
man
qatar
hospit
sever
respiratori
failur
london
public
health
england
isol
mer
viru
patient
determin
presenc
neutral
antibodi
recoveri
initi
ill
suitabl
cellclon
approach
memori
b
cell
obtain
patient
eight
month
onset
mer
infect
may
neutral
antibodi
still
detect
peripher
blood
supernat
singl
antibodyproduc
b
cell
clone
test
viru
neutral
use
pseudotyp
neutral
assay
assay
rapidli
develop
sequenc
homolog
merscov
spike
protein
avail
despit
weak
neutral
serum
titer
identifi
one
b
cell
clone
among
b
cell
clone
test
produc
monoclon
antibodi
dub
potent
neutral
activ
merscov
pseudoviru
stabl
cho
cell
line
produc
neutral
antibodi
establish
allow
product
high
yield
note
entir
project
took
four
month
draw
blood
sampl
establish
stabl
cho
cell
line
produc
fig
effici
neutral
infecti
merscov
london
patient
well
addit
isol
obtain
saudi
arabia
jordan
valu
ngml
ngml
ngml
isol
furthermor
effici
neutral
panel
monoclon
antibodyresist
viral
mutant
marm
previous
select
use
phagederiv
antibodi
map
differ
region
receptorbind
domain
rbd
spike
protein
found
target
receptorbind
domain
rbd
spike
protein
viru
spike
protein
mediat
bind
also
known
dipeptidyl
peptidas
serv
host
cell
receptor
merscov
facil
cell
entri
viru
membran
fusion
show
subnanomolar
affin
spike
protein
k
nm
higher
compar
human
receptor
epitop
recogn
identifi
use
combin
comput
predict
experiment
valid
gener
escap
variant
accord
predict
model
footprint
rbd
shown
partial
overlap
receptor
model
confirm
result
crosscompetit
experi
show
prevent
bind
rbd
thu
demonstr
neutral
merscov
infect
block
bind
cellular
receptor
rapid
isol
also
parallel
rapid
develop
anim
model
merscov
base
transient
express
human
receptor
wildtyp
immunedefici
mice
model
show
high
efficaci
prophylaxi
therapi
reduc
lung
viral
titer
well
reduc
diseas
sign
patholog
research
demonstr
sever
find
applic
viral
emerg
diseas
vaccin
medic
current
avail
also
rais
import
consider
futur
research
emerg
isol
memori
b
cell
convalesc
patient
allow
swift
gener
effect
therapeut
antibodi
rapid
develop
path
test
new
therapeut
clinic
implement
combat
emerg
viru
outbreak
import
regulatori
agenc
global
public
health
author
continu
implement
support
adapt
clinic
trial
design
aim
test
compar
multipl
candid
drug
outbreak
repres
promis
approach
prevent
therapi
merscov
infect
antibodi
isol
recov
mer
patient
natur
affinitymatur
fulli
human
monoclon
antibodi
potent
neutral
merscov
infect
multipl
isol
vitro
vivo
prevent
interact
viral
spike
protein
cellular
receptor
product
finish
preclin
develop
gmpapprov
cell
line
express
purifi
highli
potent
antibodi
high
concentr
establish
nonprofit
develop
path
reduc
endus
cost
consider
